Position in EXEL
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$227,760
New position
Shares Held
4,186
first reported quarter
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#567
of 754 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026DAYMARK WEALTH PARTNERS, LLC holds $5,277,793 across 8 Biotechnology names. EXEL ranks #7 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
55,834 | $3,067,519 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,193 | $592,598 | |
| 3 | NUVB |
Nuvation Bio Inc.
|
56,734 | $322,249 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
8,000 | $312,080 | |
| 5 | MRNA |
Moderna, Inc.
|
4,103 | $287,333 | |
| 6 | RPRX |
Royalty Pharma plc
|
4,568 | $256,127 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
4,186 | $227,760 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,994 | $212,127 |
All Filings in EXEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $227,760 | 4,186 | Shares | Sole | 2026-07-31 | |
| No filing history on record for this holder in this stock. | ||||||